Printer Friendly

IOMED AND ALLERGAN HERBERT ANNOUNCE COLLABORATIVE RESEARCH AGREEMENT AT MABON SECURITIES' DRUG DELIVERY CONFERENCE

 IOMED AND ALLERGAN HERBERT ANNOUNCE COLLABORATIVE RESEARCH
 AGREEMENT AT MABON SECURITIES' DRUG DELIVERY CONFERENCE
 SALT LAKE CITY, Feb. 19 /PRNewswire/ -- IOMED, Inc., the world leader in iontophoretic drug delivery products, and Allergan Herbert, the skin care division of Allergan, Inc. (NYSE: AGN), announced that they have entered a collaborative research agreement to develop IOMED's iontophoretic drug delivery technology and Allergan Herbert's topical anti-fungal product, NAFTIN (naftine hydrochloride) for the treatment of onychomycosis, a wide-spread fungal nail infection.
 Addressing the financial community at Mabon Securities' Drug Delivery Conference in New York this morning, Ned M. Weinshenker, Ph.D., IOMED's CEO, said, "We are very excited about this opportunity. This is IOMED's first strategic alliance with a major pharmaceutical company. We are very pleased to be working with a company of Allergan Herbert's caliber.
 "We believe this product could eventually address a very significant market. Onychomycosis is an intractable fungal infection of the finger and toe nails that afflicts several million sufferers in the U.S. alone. While the market is there, current treatments are often ineffective, frustrating and sometimes painful."
 NAFTIN has demonstrated its effectiveness in in-vitro testing against the organisms most often responsible for onychomycosis. It was first marketed in the United States by Allergan Herbert in 1989 to treat tinea, a fungal infection of the skin.
 IOMED submitted an Investigational New Drug Application (IND) with the Food and Drug Administration this month. Multi-center Phase I/II clinical trials will begin in April. Based on the results of these early studies, the companies will evaluate entering Phase III clinical trials and the details of a co-marketing arrangement.
 Allergan, Inc. headquartered in Irvine, Calif., is a global provider of specialty therapeutic products, and is now expanding beyond skin care and its leadership position in eye care.
 IOMED, Inc., is the leading developer, producer and supplier of clinical iontophoretic drug delivery products -- a technology that uses a painless and minute electrical charge to transport drugs into and across the skin. IOMED's products have been used by health care professionals in almost five million patient applications. The company believes the medical community will increasingly adopt iontophoresis as the benefits of a non-invasive, localized drug delivery modality receives wider recognition.
 -0- 2/19/92
 /CONTACT: Tom Parkinson, Ph.D., vice president-R&D of IOMED, 801-975-1191; Jeff D'Eliscu of Allergan, 714-752-4636; or Lise Needham of the Financial Relations Board, 415-986-1591, for IOMED/
 (AGN) CO: IOMED, Inc.; Allergan, Inc. ST: Utah, California IN: MTC SU:


GK -- NY055 -- 0479 02/19/92 13:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1992
Words:418
Previous Article:SPIEGEL, INC. REPORTS FOURTH QUARTER AND FULL YEAR 1991 RESULTS
Next Article:MESA/BLUEMOON RECORDINGS WINS THE GAVIN REPORT 1992 'JAZZ/ADULT ALTERNATIVE INDEPENDENT LABEL OF THE YEAR' AWARD FOR THE SECOND YEAR
Topics:


Related Articles
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
DERMION, A SUBSIDIARY OF IOMED, INC. ENTERS INTO RESEARCH AND DEVELOPMENT AGREEMENT WITH CIBA PHARMACEUTICALS
CyDex and Allergan Enter into Option Agreement on Drug Formulation Technology
CyDex and Allergan Announce the Signing of a CAPTISOL(R) Licensing Agreement.
Aurora Biosciences Announces Ion Channel Discovery Collaboration With Allergan, Inc.
Allergan and EntreMed Announce Strategic Alliance for Eye Diseases; Allergan to Develop EntreMed's Panzem(TM) for Treatment of Ophthalmic Indications...
Oculex Pharmaceuticals Announces Joint Development Agreement With Allergan for EntreMed Compound.
Discovery Partners International, Inc. and Allergan Enter Into Lead Finding Collaboration.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters